中国生物制药（01177）今日盘中大涨5.02%，引发市场关注。该股价的上涨与整个创新药板块的强劲表现密切相关，显示出投资者对该领域的信心正在增强。
据悉，创新药概念股今日普遍上扬。除中国生物制药外，恒瑞医药、绿叶制药等多只创新药股票也出现不同程度的上涨。汇丰银行最新研究报告指出，年初至今内地医药股整体跑赢大市，该行预计这一强劲势头将会持续。汇丰持续看好创新药领域，预期2026至2029年将有多款新药推出，且今年下半年公布的临床数据有望进一步推动对外授权合作。
此外，花旗银行近期上调了多家中国药企的目标价，其中包括中国生物制药。花旗将中国生物制药的目标价从6.2港元上调至8.8港元。这一调整主要基于下一代免疫肿瘤疗法的巨大市场潜力。花旗预计，下一代免疫疗法药物的总市场规模可能超过620亿美元，这一庞大的市场前景正吸引投资者的目光。中国生物制药在免疫肿瘤治疗领域的持续发力，以及其在该领域积极寻求合作与发展的决心，可能是推动其股价上涨的重要因素之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.